Dedicated support provided with every CRENESSITY prescription

A free, comprehensive program designed to ensure you and your patients receive the support and guidance they need to start and continue on CRENESSITY. Prescribe confidently with the Enrollment Form below.

Enrollment Form

Your dedicated Care Coordinator, working with an experienced clinical pharmacist, is the central point of contact for you and your patients to offer one-on-one guidance and to answer any questions about CRENESSITY, including how to access their treatment.

For you: Experienced clinical pharmacists partner with you to support your personalized care plan for each patient prescribed CRENESSITY.

For your staff: A dedicated Care Coordinator provides comprehensive assistance navigating the insurance process.

For your patients: The same dedicated Care Coordinator will provide one-on-one support to help your patients start and continue on CRENESSITY.

Our commitment is simple and unwavering: to help every patient who needs CRENESSITY have access to treatment.

Financial support options

Commercially insured patients?

CRENESSITY Savings Program: Your patients can expect to pay $0 out of pocket for their CRENESSITY prescription if they have commercial insurance.*

Insurance delaying a patient’s new prescription?

QuickStart Program: In the event of coverage delays, we’re committed to ensuring that your patients can initiate treatment by offering 30 days of free CRENESSITY.*

Patients without insurance or resources?

Patient Assistance Program (PAP): This program is designed to help patients without insurance, whose insurance doesn’t cover CRENESSITY, or who lack the financial resources to pay for their prescription. PAP provides medication at no cost.*

Changes in your patient’s coverage?

It’s important that you or your patient inform your Care Coordinator of any insurance updates as soon as possible.

  • *Subject to eligibility; additional terms and conditions apply.

CAH=congenital adrenal hyperplasia; GC=glucocorticoid.

INDICATION

CRENESSITY (crinecerfont) is indicated as adjunctive treatment to glucocorticoid replacement to control androgens in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH).

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

CRENESSITY is contraindicated in patients with hypersensitivity to crinecerfont or any excipients of CRENESSITY.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions. A hypersensitivity reaction, including throat tightness, angioedema, and generalized rash, occurred in a subject after 3 days of treatment with CRENESSITY. If a clinically significant hypersensitivity reaction occurs, initiate appropriate therapy and discontinue CRENESSITY.

Risk of Acute Adrenal Insufficiency or Adrenal Crisis with Inadequate Concomitant Glucocorticoid Therapy. Acute adrenal insufficiency or adrenal crisis, which is potentially life-threatening, can occur in patients with underlying adrenal insufficiency who are on inadequate daily glucocorticoid doses, especially in situations associated with increased cortisol need, such as acute intercurrent illness, serious trauma, or surgical procedures. Continue glucocorticoids upon initiation of and during treatment with CRENESSITY. Do not reduce the glucocorticoid dose below the dose required for cortisol replacement. Patients should continue to use stress dosing of glucocorticoids in cases of increased cortisol need.

ADVERSE REACTIONS

In adult patients, the most common adverse reactions (at least 4% for CRENESSITY and greater than placebo) are fatigue, headache, dizziness, arthralgia, back pain, decreased appetite, and myalgia.

In pediatric patients, the most common adverse reactions (at least 4% for CRENESSITY and greater than placebo) are headache, abdominal pain, fatigue, nasal congestion, and epistaxis.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.

Dosage Forms and Strengths:

CRENESSITY is available in 50 mg and 100 mg capsules, and as an oral solution of 50 mg/mL.

Please see full Prescribing Information.